Journal Watch · JAMA · 2026

Hospital Adoption and Pricing for Oncology Biosimilars.

Increases in hospital markup margins were associated with increased adoption of biosimilars, rising from a 32%, 37%, and 18% share of bevacizumab, trastuzumab, and rituximab use in 2020 to 93%, 87%, and 84% by 2024.<h4>Conclusions and relevance</h4>Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.

Robinson JC, Kosorukov AD, Whaley CMJAMA4 min readPharma relevance 75/100

DOI: 10.1001/jama.2026.1777PMID: 41811336Study type: clinical study

TL;DR

Increases in hospital markup margins were associated with increased adoption of biosimilars, rising from a 32%, 37%, and 18% share of bevacizumab, trastuzumab, and rituximab use in 2020 to 93%, 87%, and 84% by 2024.<h4>Conclusions and relevance</h4>Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.

Key findings

  • Increases in hospital markup margins were associated with increased adoption of biosimilars, rising from a 32%, 37%, and 18% share of bevacizumab, trastuzumab, and rituximab use in 2020 to 93%, 87%, and 84% by 2024.<h4>Conclusions and relevance</h4>Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.

Numbers at a glance (from the abstract)

60%72%63%32%36%34%95%37%18%93%87%84%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The reimbursement prices paid by insurers to hospitals declined more slowly, at 32%, 36%, and 34%, allowing an increase in hospital markup margins. In multivariable regression analyses, each additional dollar of acquisition price was associated with $2.72 in higher hospital reimbursement for bevacizumab (95% CI, $0.51-$4.93), $1.82 for trastuzumab (95% CI, $1.27-2.38), and $2.32 for rituximab (95% CI, $1.56-$3.09).

Full abstract (original)

Background: <h4>Importance</h4>Many physician-administered oncology biologics are losing patent protection in the coming years and will face competition from biosimilars. Hospitals and insurers share a mutual interest in developing payment methods that share the potential savings from adopting these less costly agents.<h4>Objective</h4>To test whether hospitals paid lower acquisition prices and earned higher markup margins for physician-administered oncology biosimilars; whether insurers reduced the reimbursement prices they paid to hospitals, thereby sharing in the savings from lower manufacturer prices; and whether reductions in acquisition prices and increases in hospital margins were associated with accelerated adoption of biosimilars.<h4>Design, setting, and participants</h4>Observational study using 2020-2024 data for patients covered by Blue Cross Blue Shield health insurance, linked to information on drug acquisition prices paid by hospitals to manufacturers; drug reimbursement prices paid by insurers to hospitals; hospital eligibility for federal 340B price discounts; and other hospital, patient, and market characteristics.<h4>Exposures</h4>Biologics and biosimilars acquired by hospitals from manufacturers at one price and reimbursed by private insurers at a higher price.<h4>Main outcomes and measures</h4>Acquisition prices paid by hospitals to manufacturers, reimbursement prices paid by insurers to hospitals, hospital drug price markup margin, hospital adoption of biosimilars.<h4>Results</h4>Between 2020 and 2024 (66 139 patients who received oncology biologics and biosimilars in 1541 hospitals), acquisition prices paid by hospitals to drug manufacturers declined by 60%, 72%, and 63% for the biosimilars of bevacizumab, trastuzumab, and rituximab, respectively.

What they did: The reimbursement prices paid by insurers to hospitals declined more slowly, at 32%, 36%, and 34%, allowing an increase in hospital markup margins. In multivariable regression analyses, each additional dollar of acquisition price was associated with $2.72 in higher hospital reimbursement for bevacizumab (95% CI, $0.51-$4.93), $1.82 for trastuzumab (95% CI, $1.27-2.38), and $2.32 for rituximab (95% CI, $1.56-$3.09).

Results & conclusions: Increases in hospital markup margins were associated with increased adoption of biosimilars, rising from a 32%, 37%, and 18% share of bevacizumab, trastuzumab, and rituximab use in 2020 to 93%, 87%, and 84% by 2024.<h4>Conclusions and relevance</h4>Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.

Abstract © the authors / JAMA (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1001/jama.2026.1777 · PubMed 41811336.

Why it matters for pharma & biotech

  • Relevant to General & Medicine teams tracking JAMA for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this JAMA study find?

Increases in hospital markup margins were associated with increased adoption of biosimilars, rising from a 32%, 37%, and 18% share of bevacizumab, trastuzumab, and rituximab use in 2020 to 93%, 87%, and 84% by 2024.<h4>Conclusions and relevance</h4>Hospital price markup margins from the administration of oncology biosimilars have increased over time and have been accompanied by large increases in the utilization of these therapies.

What type of study is this?

It is a clinical study, published in JAMA in 2026. The reimbursement prices paid by insurers to hospitals declined more slowly, at 32%, 36%, and 34%, allowing an increase in hospital markup margins.

Where can I read the original paper?

The original is at the publisher via DOI 10.1001/jama.2026.1777. PubMed ID: 41811336. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Robinson JC, Kosorukov AD, Whaley CM. Hospital Adoption and Pricing for Oncology Biosimilars.. JAMA (2026). DOI: 10.1001/jama.2026.1777.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/hospital-adoption-and-pricing-for-oncology-biosimilars-261777/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides